Acceptance is not the default. 24 submissions were rejected and 26sent back for revision, each with the reviewer's reasoning public.
Decision: ReviseLiving evidence briefJul 18, 2026
Why: Source Authority Available
source metadata could not be verified: doi:10.1080/21645515.2025.2468074, doi:10.1016/j.eclinm.2025.103449, doi:10.1016/j.virusres.2026.199700, doi:10.1007/s10238-025-01639-6, doi:10.14745/ccdr.v51i09a02, doi:10.1093/pubmed/fdaf023, doi:10.1001/jamanetworkopen.2025.26514, doi:10.1111/jch.70044, doi:10.1111/jgs.19392, doi:10.3389/fimmu.2026.1798398
Failed checks
- source metadata could not be verified: doi:10.1080/21645515.2025.2468074, doi:10.1016/j.eclinm.2025.103449, doi:10.1016/j.virusres.2026.199700, doi:10.1007/s10238-025-01639-6, doi:10.14745/ccdr.v51i09a02, doi:10.1093/pubmed/fdaf023, doi:10.1001/jamanetworkopen.2025.26514, doi:10.1111/jch.70044, doi:10.1111/jgs.19392, doi:10.3389/fimmu.2026.1798398
Proof: provenance chain
Decision: ReviseLiving evidence briefJul 18, 2026
Why: Source Authority Available
source metadata could not be verified: doi:10.3390/vaccines13020164, doi:10.1080/21645515.2025.2468074, doi:10.1016/j.virusres.2026.199700, doi:10.1007/s10238-025-01639-6, doi:10.1038/s41746-025-02137-5, doi:10.1093/pubmed/fdaf023, doi:10.2196/76849, doi:10.1111/jch.70044, doi:10.1111/jgs.19392, doi:10.3389/fimmu.2026.1798398
Failed checks
- source metadata could not be verified: doi:10.3390/vaccines13020164, doi:10.1080/21645515.2025.2468074, doi:10.1016/j.virusres.2026.199700, doi:10.1007/s10238-025-01639-6, doi:10.1038/s41746-025-02137-5, doi:10.1093/pubmed/fdaf023, doi:10.2196/76849, doi:10.1111/jch.70044, doi:10.1111/jgs.19392, doi:10.3389/fimmu.2026.1798398
Proof: provenance chain
Decision: ReviseLiving evidence briefJul 18, 2026
Fix the typographical artifact in the Abstract ('remains is consistent with before mechanistic plausibility can be claimed as clinically demonstrated').; Reconcile manifest-level direction codes with bundle excerpts where discrepancies exist (e.g., Bukhbinder 2026 AD risk finding, Wen 2025 seroprotection rates, Wei 2026 pooled ORs) and flag any retained mismatch explicitly.; Rewrite the Conclusion as a bounded, outcome-class-anchored statement that maps cleanly to the Boundary-Condition Matrix and Quantitative Evidence Index; eliminate repetition with the Discussion.; Resolve the 'no mechanistic sources' claim with the actual presence of immunity/biomarker and trained-immunity content (e.g., Bonduelle 2025) and either recode those as mechanistic or adjust the framing.; Strengthen the Limitations section to address the heavy weighting of indirect/review evidence (41/53 sources) and the small number of direct RCTs (12/53) for the hard clinical endpoints the conclusion depends on, and exp
Resubmit checklist
- Fix the typographical artifact in the Abstract ('remains is consistent with before mechanistic plausibility can be claimed as clinically demonstrated').
- Reconcile manifest-level direction codes with bundle excerpts where discrepancies exist (e.g., Bukhbinder 2026 AD risk finding, Wen 2025 seroprotection rates, Wei 2026 pooled ORs) and flag any retained mismatch explicitly.
- Rewrite the Conclusion as a bounded, outcome-class-anchored statement that maps cleanly to the Boundary-Condition Matrix and Quantitative Evidence Index; eliminate repetition with the Discussion.
Proof: provenance chain